We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Charles River Laboratories
CRL
$11.2B
| $31.6M | 0.17% |
+208,552
| New | +$27.8M |
|
|
ANSS
177
DELISTED
Ansys
ANSS
| $31.6M | 0.17% |
90,010
-18,628
| -17% | -$6.1M |
|
178
Simply Good Foods
SMPL
$901M
| $31.6M | 0.17% |
1,000,227
-664,528
| -40% | -$23.1M |
|
179
Ford
F
$58.5B
| $31.6M | 0.17% |
2,911,801
+1,176,100
| +68% | +$12M |
|
180
Vornado Realty Trust
VNO
$7.41B
| $31.5M | 0.17% |
824,596
+224,722
| +37% | +$8.41M |
|
181
Packaging Corp of America
PKG
$21.9B
| $31.5M | 0.17% |
167,297
+19,390
| +13% | +$3.67M |
|
182
Palantir
PLTR
$295B
| $31.4M | 0.17% |
230,090
+56,911
| +33% | +$6.67M |
|
183
Flex
FLEX
$41.7B
| $31.2M | 0.16% |
+624,745
| New | +$24.3M |
|
184
Tango Therapeutics
TNGX
$4.43B
| $30.9M | 0.16% |
6,029,906
+5,523,718
| +1,091% | +$13.7M |
|
185
Regeneron Pharmaceuticals
REGN
$78.5B
| $30.9M | 0.16% |
58,778
-47,439
| -45% | -$26.5M |
|
|
MASI
186
DELISTED
Masimo
MASI
| $30.7M | 0.16% |
182,709
+49,740
| +37% | +$7.94M |
|
187
Philip Morris
PM
$297B
| $30.7M | 0.16% |
168,366
+37,004
| +28% | +$6.35M |
|
|
TTAN
188
ServiceTitan Inc
TTAN
$7.92B
| $30.6M | 0.16% |
285,691
+283,550
| +13,244% | +$31.7M |
|
189
Celldex Therapeutics
CLDX
$2.99B
| $30.5M | 0.16% |
1,500,455
+312,026
| +26% | +$6.07M |
|
190
Ametek
AME
$55.4B
| $30.5M | 0.16% |
168,323
+90,167
| +115% | +$15.5M |
|
191
MongoDB
MDB
$27.1B
| $30.4M | 0.16% |
144,886
-177,322
| -55% | -$32.8M |
|
192
International Flavors & Fragrances
IFF
$20.2B
| $30.2M | 0.16% |
411,143
+86,346
| +27% | +$6.52M |
|
193
ODDITY Tech
ODD
$654M
| $30.2M | 0.16% |
400,112
-40,421
| -9% | -$2.46M |
|
194
TD Synnex
SNX
$20.4B
| $29.9M | 0.16% |
220,548
+213,763
| +3,151% | +$25.1M |
|
195
Curtiss-Wright
CW
$26.7B
| $29.9M | 0.16% |
61,218
-6,009
| -9% | -$2.37M |
|
196
Group 1 Automotive
GPI
$3.42B
| $29.9M | 0.16% |
68,401
+53,155
| +349% | +$22.3M |
|
197
Archer Daniels Midland
ADM
$38.2B
| $29.7M | 0.16% |
561,878
+521,449
| +1,290% | +$25.4M |
|
198
Coca-Cola
KO
$377B
| $29.6M | 0.16% |
419,030
+91,921
| +28% | +$6.55M |
|
199
IBM
IBM
$211B
| $29.6M | 0.16% |
100,531
-79,857
| -44% | -$20.6M |
|
200
Portillo's
PTLO
$331M
| $29.5M | 0.16% |
2,527,236
+1,774,763
| +236% | +$20.5M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.